Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Gene Review:

Alan1 - alloantigen response 1

Mus musculus

Havelková, H. et al., Ehrke, M.J. et al., Lipoldova, M., Hultman, C.S. et al., Holán, V. et al.

Marie Lipoldova,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Alan1 .

Alloreactivity is the strongest known primary immune response. Its clinical manifestations are graft rejection, graft-versus-host disease and graft-leukemia effect.

High impact information on Alan1

The "interleukin 2-like" activity was indistinguishable from that of partially purified interleukin 2 in terms of ability to restore responsiveness to experimentally inhibited primary alloantigen response cultures and to maintain long-term cultures of activated T-cells [1].

Biological context of Alan1

A novel alloreactivity-controlling locus, Alan1 was mapped to mouse chromosome 17 [2].

Analytical, diagnostic and therapeutic context of Alan1

The purpose of this study was to determine if the immunosuppression of burn injury might affect the alloantigen response and minimize sensitization to CK allografts [3].

As MLR reflects the recognition phase of transplantation reaction, identification of human counterparts of the Alan genes and a better understanding of the regulation of alloresponsiveness might lead to a better prediction of patients' reactions to allografts and to a more individualized measures to prevent rejection [4].

References

Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Ehrke, M.J., Maccubbin, D., Ryoyama, K., Cohen, S.A., Mihich, E. Cancer Res. (1986) [Pubmed]
A novel alloreactivity-controlling locus, Alan1, mapped to mouse chromosome 17. Holán, V., Havelková, H., Krulová, M., Demant, P., Lipoldová, M. Immunogenetics (2000) [Pubmed]
Burn injury impairs second-set rejection and CTL reactivity in mice primed by cultured keratinocyte allografts. Hultman, C.S., Cairns, B.A., deSerres, S., Frelinger, J.A., Meyer, A.A. Transplantation (1995) [Pubmed]
A new type of genetic regulation of allogeneic response. A novel locus on mouse chromosome 4, Alan2 controls MLC reactivity to three different alloantigens: C57BL/10, BALB/c and CBA. Havelková, H., Badalová, J., Demant, P., Lipoldová, M. Genes Immun. (2000) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use

[search][advanced]